Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 11/20 | 0.38 |
| ▸ | IL1B | P01584 | 7/20 | 0.35 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.35 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.35 |
| ▸ | CCNK | O75909 | 1/20 | 0.35 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
| ▸ | CDK9 | P50750 | 1/20 | 0.35 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.35 |
| ▸ | EHMT2 | Q96KQ7 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25302031 | 1.00 | NLRP3 (0.38) | NLRP3IL1BEGLN2CCNT1CCNK | |
| SCHEMBL30488522 | 1.00 | NLRP3 (0.38) | NLRP3IL1BEGLN2CCNT1CCNK | |
| SCHEMBL30833993 | 0.95 | NLRP3 (0.34) | NLRP3IL1BEGLN2CCNT1CCNK | |
| SCHEMBL30833878 | 0.91 | NLRP3 (0.42) | NLRP3CCNT1CCNKCCNE1CDK2 | |
| SCHEMBL30833913 | 0.91 | CCNK (0.34) | NLRP3CCNT1CCNKCCNE1CDK2 | |
| SCHEMBL29030501 | 0.90 | NLRP3 (0.41) | NLRP3IL1BEHMT2 | |
| SCHEMBL29030496 | 0.90 | NLRP3 (0.41) | NLRP3IL1BEHMT2 | |
| SCHEMBL30834010 | 0.90 | NLRP3 (0.44) | NLRP3IL1BCCNT1CCNKCCNE1 | |
| SCHEMBL25303599 | 0.87 | NLRP3 (0.38) | NLRP3IL1BCCNT1CCNKCCNE1 | |
| SCHEMBL25303600 | 0.87 | NLRP3 (0.38) | NLRP3IL1BCCNT1CCNKCCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250152584-A1 | NLRP3 INFLAMMASOME INHIBITOR AND USES THEREOF | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2025-05-15 | — | — | US | disclosed |
| EP-4461729-A1 | ANTIGEN BINDING PROTEIN TARGETING MSLN AND USE THEREOF | Transthera Sciences (Nanjing), Inc. (CN) | 2024-11-13 | — | — | EP | disclosed |
| WO-2023131277-A1 | NLRP3 INFLAMMASOME INHIBITOR AND USES THEREOF | 药捷安康(南京)科技股份有限公司 | 2023-07-13 | — | — | WO | disclosed |
| CN-116410140-A | NLRP3 inflammation corpuscle inhibitor and application thereof | 药捷安康(南京)科技股份有限公司 | 2023-07-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250152584-A1 | NLRP3 INFLAMMASOME INHIBITOR AND USES THEREOF | NLRP3, NLRP1, PYCARD | NLRP3 1/4885IL1B 7/4885EGLN2 1128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.